LQDA - Liquidia Technologies, Inc.
| Previous Close | 6.29 |
| Open | 6.13 |
| Bid | 5.99 x 1100 |
| Ask | 9.48 x 1200 |
| Day's Range | 5.91 - 6.36 |
| 52 Week Range | 5.78 - 38.46 |
| Volume | 135,117 |
| Avg. Volume | 72,548 |
| Market Cap | 111.669M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.58 |
| Earnings Date | Oct 29, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.50 |
- GlobeNewswire
Liquidia to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.
- GlobeNewswire
Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host.
- GlobeNewswire
Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- Simply Wall St.
Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?
Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)
Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
- American City Business Journals
Behind Liquidia's new deal with GSK
As a Triangle company rapidly approaches filling for approval of its first drug, it has inked a deal with GlaxoSmithKline to bring more drugs up the pipeline behind it.
- GlobeNewswire
Liquidia and GSK Restructure Collaboration Agreement
Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that it has amended its collaboration agreement with GlaxoSmithKline (GSK) for the development and commercialization of pharmaceuticals based upon the Company’s proprietary PRINT® technology delivered through the inhalation route of administration. The amended collaboration agreement provides the Company with the right to develop and commercialize three additional PRINT®-based therapeutics delivered via inhalation. Additionally, under the amended collaboration agreement, the Company can acquire rights to pursue additional PRINT®-based programs for inhalation therapy, subject to GSK’s approval.
- GlobeNewswire
Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019
Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 (single capsule, 1-2 breaths) correlates with the 54 mcg dose of Tyvaso® (9 breaths), the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavailability and pharmacokinetics (PK) of single doses of LIQ861 and Tyvaso in 18 PAH patients. The company targets NDA submission in late 2019 that will include additional data generated from ongoing development activities.
- GlobeNewswire
Liquidia to Present at Jefferies Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., June 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, announced that Neal.
- GlobeNewswire
Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO). Dr. Katz joins Liquidia with more than 20 years of experience in healthcare finance and corporate development. Most recently, he served as CFO at Argos Therapeutics.
- GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced that Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division, Professor of Medicine at Tufts University School of Medicine, and INSPIRE Principal Investigator, will present a poster highlighting data from Liquidia’s Phase 3 INSPIRE trial of LIQ861 for the treatment of pulmonary arterial hypertension (PAH) at the ATS International Conference in Dallas, Texas. The poster will include data on tolerability of LIQ861 and selected exploratory endpoints at two months of treatment, split by New York Heart Association Functional Class.
- GlobeNewswire
Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating Pulmonary Arterial HypertensionOn Track for Planned New Drug Application (NDA) Submission for LIQ861 in.
- GlobeNewswire
Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019
RESEARCH TRIANGLE PARK, N.C., April 23, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- GlobeNewswire
Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed safety and exploratory endpoint findings at the two-month timepoint for the Phase 3 INSPIRE trial. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, presented the data at the opening plenary session of the 39th International Society for Heart & Lung Transplantation (ISHLT) Meeting and Scientific Sessions in Orlando, Florida. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using its PRINT® Technology, as an alternative to current inhaled treprostinil therapy for the treatment of patients with pulmonary arterial hypertension (PAH) (WHO Group 1).
- GlobeNewswire
Liquidia Technologies to Present at Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- GlobeNewswire
Liquidia Technologies Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., March 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- GlobeNewswire
Liquidia Technologies Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., March 21, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- American City Business Journals
Morrisville company looks to Wall Street — again
Less than a year after its IPO, this Morrisville company wants to raise more cash to fund its core competencies.
- GlobeNewswire
Liquidia Technologies Announces Proposed Offering of Common Stock
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire
Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line results of its pivotal Phase 3 INSPIRE study in patients with pulmonary arterial hypertension (“PAH”) treated with LIQ861, the first inhaled dry powder formulation of treprostinil. Initial analysis indicates the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, stated: “The top-line analysis of LIQ861 from the INSPIRE study is highly encouraging for physicians and patients.
- GlobeNewswire
Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trialAccepted by FDA into Emerging Technology Program to support review of PRINT®.
- GlobeNewswire
Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
- GlobeNewswire
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today reported positive interim safety data from its open-label, multicenter Phase 3 clinical trial (INSPIRE) evaluating LIQ861, an inhaled dry powder formulation of treprostinil, for the treatment of pulmonary arterial hypertension (“PAH”). Patients adding LIQ861 to current non-prostacyclin oral therapies started at a dose of approximately 25 mcg and those transitioned from nebulizer-delivered treprostinil at a stable dose were initiated at a dose of LIQ861 lower than their current stable treprostinil dose.
- GlobeNewswire
Liquidia Technologies Provides Leadership Update
Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that Kevin Gordon, President and Chief Financial Officer, plans to retire from his current role at Liquidia to focus on board and other advisory work. Liquidia has initiated a search process for a new CFO and Mr. Gordon has agreed to continue his employment with the company until March 1, 2019 to support a smooth transition. “On behalf of Liquidia’s employees and Board of Directors, I want to thank Kevin for his many contributions and wish him the best in his next chapter,” stated Neal Fowler, Chief Executive Officer of Liquidia.
- Simply Wall St.
Liquidia Technologies Inc (NASDAQ:LQDA): Time For A Financial Health Check
Liquidia Technologies Inc (NASDAQ:LQDA) is a small-cap stock with a market capitalization of US$309m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
